Telomir (TELO) Director MacPherson Receives 50,000-Option Grant

What Happened
MacPherson Edward Clouston, a director of Telomir Pharmaceuticals, was granted 50,000 stock options on April 16, 2026. The Form 4 reports the acquisition as a derivative award at $0.00, with a footnote stating the exercise price equals the company’s closing common-stock price on the grant date. The options were issued under the Issuer’s 2023 Omnibus Incentive Plan and vested immediately upon issuance.

Key Details

• Transaction date: April 16, 2026 (reported on Form 4 filed July 27, 2026).
• Transaction type/code: Grant/Award (A) of 50,000 stock options.
• Reported acquisition value: $0.00 (derivative award); exercise price = closing price on 4/16/2026 (Footnote F1).
• Plan and vesting: Issued under the 2023 Omnibus Incentive Plan; all options vested immediately (Footnote F2).
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing date (2026-07-27) is well after the transaction date — this appears to be a late Form 4 filing.

Context
These were option grants (derivative securities), not an outright stock purchase or sale; no shares were reported as exercised or sold in this filing. Director option grants are commonly used as compensation and do not by themselves indicate immediate buying or selling activity. The late filing reduces short-term transparency for investors and may warrant attention but does not change the substance of the grant.